3
项与 Autologous gamma delta T cell therapy (TC BioPharm) 相关的临床试验Safety and Efficacy of Ex-vivo Expanded Allogeneic γδ T-lymphocytes (OmnImmune®) in Patients With Active Relapsed or Refractory Acute Myeloid Leukaemia (AML) Who Are Not Eligible for or do Not Consent to High Dose Salvage Chemotherapy and/or Allogeneic Haematopoietic Cell Transplantation (HCT). A Dose Escalation, Open-label, Phase I Study
This study investigates the potential curative properties of gamma delta T-cells obtained from a blood-related donor of an AML patient.
Adaptive Study of the Safety, Tolerability & Efficacy of Autologous γδ T Lymphocyte Therapy (ImmuniCell®) in Patients With Advanced Cancers Refractory to Current Treatment or Have Indolent Disease for Which Immunotherapy May be Beneficial
To determine the safety, tolerability, maximum tolerated dose (MTD) and efficacy of ImmuniCell® in patients with melanoma, renal cell cancer (RCC) or non-small cell lung cancer (NSCLC). The study is an adaptive design that has 3 stages: Stage 1 - dose escalation, Stage 2 - efficacy, and Stage 3 - confirm efficacy in one of the tumor types.
Adoptive immunotherapy using zoledronate-expanded autologous gamma/delta T cells for patients with non-small cell lung cancer refractory to standard treatment. - Zoledronate-expanded autologous gamma/delta T cell therapy for NSCLC
100 项与 Autologous gamma delta T cell therapy (TC BioPharm) 相关的临床结果
100 项与 Autologous gamma delta T cell therapy (TC BioPharm) 相关的转化医学
100 项与 Autologous gamma delta T cell therapy (TC BioPharm) 相关的专利(医药)
100 项与 Autologous gamma delta T cell therapy (TC BioPharm) 相关的药物交易